What we're talking about when we talk about race

By Havranek E.P.   Masoudi F.A.  

Journal of the American College of Cardiology, Vol. 43, Iss. 3, 2004-02 ,pp. : 436-437

Elsevier

Access to resources Recommend Favorite

Diabetes, revascularization and CABG: When there is smoke, there is a fire!

By Dellborg Mikael   Jeppsson Anders  

Scandinavian Cardiovascular Journal, Vol. 41, Iss. 6, 2007-01 ,pp. : 355-356

Informa Healthcare

Access to resources Recommend Favorite

The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation

By Calkin A.   Giunti S.   Sheehy K.   Chew C.   Boolell V.   Rajaram Y.   Cooper M.   Jandeleit-Dahm K.  

Diabetologia, Vol. 51, Iss. 9, 2008-09 ,pp. : 1731-1740

Springer Publishing Company

Access to resources Recommend Favorite

Understanding and Modulating the Toll Like Receptors (TLRs) and NOD Like Receptors (NLRs) Cross Talk in Type 2 Diabetes

By  

Current Diabetes Reviews, Vol. 10, Iss. 3, 2014-05 ,pp. : 190-200

Bentham Science Publishers

Access to resources Recommend Favorite

Drug review - Rosuvastatin

By Chambers Scott  

Drugs In Context Primary Care Part B: Cardiovascular Medicine II, Vol. 1, Iss. 2, 2004-01 ,pp. : 55-72

CSF Medical Communications Ltd

Access to resources Recommend Favorite